

Next generation IRS Project

Developing an evidence base showing the impact and cost effectiveness of 3GIRS: Progress, challenges, and dissemination

MIM 2018 Fransisco Saute & Molly Robertson





- Cost-effectiveness compared to, or incrementally in combination with, other interventions:
 - LLINS
 - New vector control tools
 - MDA/SMC
 - Quality of Case Management (passive, active)
- Effectiveness of IRS in different transmission settings over time and space
- Benefits and ideal monitoring and evaluation of interventions to inform decision-making
- Use of evidence for targeting of IRS
- Creating mechanisms to estimate need to drive demand (decision-making)

NgenIRS Impact Analysis – Critical Data Needs



	Intervention Data	Epidemiology Data
	IRS	Suspected Cases (Fever)
	Insecticide	RDTs Performed
	Coverage	RDTs Positive (Confirmed Cases)
	Duration of Efficacy	Severe Malaria Cases
	LLINS	Malaria Deaths
	Net Type	All Cause Deaths
	Coverage	Entomology Data
	Usage Rates	Vector ID & Distribution
	Efficacy/Durability	Entomological Inoculation Rates
	Case Management	Insecticide Susceptibility
State Company	Quality of diagnosis	Feeding/Resting behaviors
S Smith Kitcher	Quality of treatment	Demographic Data
	Other Interventions	Total Population
where has a	Mass Test & Treat	Demographic Characteristics
is made and	SMC	Behavioral Characteristics
home and here and her	ІРТр	Climate Data
	Vaccine	Rainfall
	Etc	Temp

The better the data **resolution**, the stronger the analysis (e.g. IRS implementation data by village can be very useful if Epi data is aggregated to that level.)

Building an evidence base



Mali: Observational analysis of impact of IRS (including 3GIRS) from 2012-2014 in Segou Upcoming analysis of introduction of IRS in Mopti and of SumiShield

Ghana: Observational analysis of the impact of 3GIRS in Northern Ghana *Upcoming analysis of previously unsprayed*

areas and introduction of SumiShield in 2018.

VectorLink synergies: ongoing discussion

- Synthesis of decision-making processes

Global Standards:

- Costing Framework

- Standardized IRS M&E

Decision-making: - Evidence review meetings - Dissemination activities

Zambia: Retrospective evaluation of the effectiveness of IRS with Actellic on malaria transmission *Upcoming analysis of SumiShield by NMEC and possible Sylando trial.*

Mozambique: Prospective CRT to measure the health impact and cost-effectiveness of 3GIRS combined with LLINs and impact of SumiShield

Epidemiological results to be presented at the 2018 MIM

In discussions:

Burkina Faso: Observational analysis of SumiShield **Malawi**: Observational analysis of Actellic

Building an evidence base





Epidemiological impact of 3GIRS in Mali

After PMI AIRS spraying in 2014, incidence of malaria **dropped 36%** in IRS districts compared to non-IRS districts (76,260 cases averted)¹



Epidemiological impact of 3GIRS in Zambia

IRS using Actellic-CS, the first approved and widely used 3GIRS chemical, appears to substantially reduce malaria burden under standard operational conditions in Zambia. Its effectiveness was associated with twice the effect of non-Actellic IRS in this setting.



Further evidence of the overall cost-effectiveness of 3GIRS in a high- transmission setting²

Full first year results of the NgenIRS-led cluster randomized trial in Mozambique will provide are expected to be shared in October 2018 at ASTMH

Building an evidence base



Mali: Observational analysis of impact of IRS Zambia: Retrospective evaluation of the effectiveness of IRS with Actellic on malaria transmission (including 3GIRS) from 2011-2014 in Segou: - ~500K people protected over the 3 years - Association between increased coverage of IRS and reduced malaria prevalence and confirmed case incidence - ~300K cases of malaria averted Effectiveness of IRS with Actellic: ~26% reduction in the odds of malaria infection Upcoming analysis of introduction of IRS in Upcoming analysis of Sumishield by NMEC and possible Mopti and of Sumishield Sylando trial. ۰. ۵۰ Ghana: Observational analysis of the impact of **3GIRS in Northern Ghana:** Mozambique - Fewer malaria cases in IRS districts than non-IRS districts from Jan 2014 to Jan 2017 - In 2015, ~24% decrease in the number of suspected malaria cases following introduction of IRS in Kumbungu District Upcoming analysis of previously unsprayed areas and introduction of Sumishield in 2018. **Decision-making: Global Standards:** - Evidence review meetings - Costing Framework - Dissemination activities - Standardized IRS M&E - Synthesis of decision-making processes **Building Partnerships • Creating Solutions • Saving Lives** 6



Ghana

- In 2015 there was a ~24% decrease in the suspected malaria cases in IRS areas
 Mali
- Over 300K cases were averted in 3 years of IRS in the Ségou region
- The removal of IRS in Bla was associated with a 70% increase in malaria cases

Mozambique

 As part of a RCT there was a ~50% reduction in An. funestus densities over six months post intervention

Zambia

- The odds of malaria infection were reduced by ~26% in areas with IRS
- Improvement of enumeration led to increased impact through better coverage
- Combining IRS and drug-based interventions (MDA Zambia, SMC Mali) leads to a
 greater impact than either strategy alone



What do I spray and where?

• What evidence is needed to show the effect of rotation both entomologically and epidemiologically?

How is my program doing?

• What are the benefits of standardized analysis of routine data?

Is IRS worth the investment?

 What are the additional benefits that outweigh the cost of 3GIRS – how do we measure cost-effectiveness?

How does IRS fit into my toolbox?

• What is the increased effect of IRS over other tools as they become available?

At what point can I switch strategies?

 Is there a threshold at which IRS can be removed and what is the effect before this threshold?

Focus on Mozambique





.

CRT in Mozambique



A cluster randomized trial (CRT) to determine the **public health impact** & **cost effectiveness** of IRS with Pirimiphos-Methyl (Actellic®300 CS, Syngenta AG, Basel Switzerland) in communities with high levels of LLIN access

Mopeia District

7,614 km²

160,000 total population (2014 Estimate)
17,500 children <5 years (2016 Study Census)
<5 malaria prevalence = 54% (2011 DHS)
1 District Hospital and 11 local Health Facilities

An. gambiae s.l. & An. funestus s.l.





Mopeia District

175,000 LLINs distributed in 2014/15 (usage rates estimated ~40% in <5's 2011 DHS)

IRS with Deltamethrin in 2014 (36,000 structures sprayed)

 Pyrethroid resistance detected in neighboring Mocuba & Morrumbala districts in 2015

Mozambique - Overview of cost trial





Mozambique - Overview of cost trial







Crude analysis

Incidence:

- Passive
 - TPR, Incidence/village (RR)
 % positive
- Active cohort + family health economics
 - $\,\circ\,$ Incidence, RR (IRS vs no IRS)
 - $\circ\,$ Net use/behavior

Year 1 prevalence

- Odds ratio
- Net use/behavior

Analysis Considerations

- Cluster design + cluster stratification
- Confounding variables (SES, house type)
- Repeated measures for active cohort





Average number of An. funestus collected per trap-night by month

Monthly differences in the mean number of An. funestus collected in CDCLTs per trap night between non-IRS and IRS sites.

Means presented are the geometric mean number of mosquitoes collected per trapnight.

A two-way t-test compares densities from non-IRS and IRS clusters (* = p<0.05)





12-month (Dec – Nov) Cumulative Incidence Rate Ratio

	Exposed	Unexposed	Total		
Cases Person-time	9277 131328	12281 140760	21558 272088		
Incidence rate	.0706399	.0872478	.0792317		
	Point	estimate	[95% Conf	. Interval]	
Inc. rate diff.	0:	166079	0187167	014499	
Inc. rate ratio	. 80	096471	. 7880254	.8318409	(exact)
Prev. frac. ex. Prev. frac. pop	.19	903529 918771	.1681591	.2119746	(exact)
	(midp) (midp) 2 [;]	Pr(k<=9277) = *Pr(k<=9277) =	- = =	0.0000	(exact) (exact)

---No Spray ---Spray A According to the 2015 MIS, in Zambezia 56.9% of all febrile children under

According to the 2015 MIS, in Zambezia 56.9% of all febrile children unde 5 sought care at a formal health facility ¹

RR of 0.81 (Cl₉₅ 0.79 – 0.83)

Approximately 2181 u5 health facility cases averted in 12 months Adjusted for a health care utilization rate of 56% = approximately 3895 Total u5 cases averted in 6 months

¹ Ministério da Saúde (MISAU), Instituto Nacional de Estatística (INE), ICF Internacional, 2015. Inquérito de Indicadores de Imunização, Malária e

HIV/SIDA em Moçambique 2015. Maputo, Moçambique.
 Rockville, Maryland, EUA: INS, INE e ICF International.



	Study Arm			
	No Spray	Spray	Total	
Demographics				
Total participants	449 (54.9%)	369 (45.1%)	818	
Under 5	208 (46.3%)	213 (57.7%)	421 (51.5%)	
Household has at least one net	255 (56.8%)	184 (49.9%)	439 (53.7%)	
Malaria case in household, last 30 days	206 (45.9%)	170 (46.1%)	376 (46.0%)	
Sought care for malaria, last 30 days	176 (39.2%)	154 (41.7%)	330 (40.3%)	
Outcome				
RDT+	191 (42.5%)	164 (44.4%)	355 (43.4%)	

(OR=1.07, Cl₉₅ 0.80 - 1.4)



Preliminary Observations:

**These general observations are made at the highest summary levels – by spray status. Final analysis will utilize models that account for the effects of clustering, stratification, and random effects **

 Enhanced passive case detection shows a significant reduction in u5 RDT confirmed malaria incidence from IRS clusters (2017 RR=0.81)



- Very High burden district (prevalence rates > 50%)
- Low utilization of formal healthcare systems
- Good LLIN access
- Vectors still susceptible to pyrethroids

Future Directions:

- Formal analysis plan will be carried out on complete datasets (PCD, Cross, ACD) beginning 4Q 2018
- Modeling activities



Questions

Building Partnerships • Creating Solutions • Saving Lives